1. Allely MC, Alps BJ, Kilpatrick AT. The effects of the novel anti-anginal agent RS 43285 on [lactic acid], [K+] and pH in a canine model of transient myocardial ischaemia.Biochem Soc Trans 1987;15:1057?1058.
2. Brown CM, Clarke B, Fraser S, et al. Pharmacological profile of ranolazine, a metabolic modulator active in ischaemia.Br J Pharmacol 1988;93(Suppl):248.
3. Alley MC, Alps BJ. Prevention of myocardial enzyme release by ranolazine in a primate model of ischemia with reperfusion.Br J Pharmacol 1990;99:5?6.
4. Opie LH. Metabolic regulation in ischemia and hypoxia. Effects of regional ischemia on metabolism of glucose and fatty acids. Relative rates of aerobic and anaerobic energy production during myocardial infarction and comparison with effects of anoxia.Circulation 1976;38:52?68.
5. Pouleur H, Hue L, Harlow BJ, Rousseau MF. Metabolic pathway modulation: A new approach to treat myocardial ischemia?Circulation 1989;80(Suppl II):II52.